Shmuel Yaccoby
Professor
University of Arkansas for Medical Sciences
faculty
Internal Med, College of Medicine
Research Areas
Links
Is this your profile? Verify and claim your profile
Biography and Research Information
OverviewAI-generated summary
Shmuel Yaccoby's research focuses on understanding the molecular mechanisms underlying multiple myeloma and identifying potential therapeutic targets. His work investigates the role of epigenetic modifications, such as H3K4me3 broad domains, in the regulation of oncogenes, particularly in the context of super-enhancers. Yaccoby has explored the therapeutic potential of inhibiting PHF19 as a strategy for treating multiple myeloma.
His recent publications also highlight the intricate interactions within the bone marrow microenvironment. This includes studying how EDNRA-expressing mesenchymal cells contribute to disease progression and how mesenchymal stem cells influence the growth and dormancy of myeloma cells. Furthermore, his research examines altered mesenchymal and endothelial cell subsets in the bone marrow of myeloma patients and their association with disease progression. Yaccoby has also investigated the impact of mesenchymal stem cell cytotherapy, specifically the induction of HMOX1, on inhibiting osteoclastogenesis and mitigating myeloma-induced bone disease.
In addition to these areas, Yaccoby's work has explored the effects of cyclin-dependent kinase inhibitors, such as dinaciclib, on impairing homologous recombination and sensitizing multiple myeloma cells to PARP inhibition. He maintains collaborations with researchers at the University of Arkansas for Medical Sciences, including Robert J. Shmookler Reis, Srinivas Ayyadevara, Syed J. Mehdi, and Michele Cottler‐Fox, with whom he has co-authored multiple publications.
Metrics
- h-index: 46
- Publications: 199
- Citations: 8,037
Selected Publications
- Induction of HMOX1 by mesenchymal stem cell cytotherapy inhibits osteoclastogenesis and myeloma‐induced bone disease (2025) DOI
- EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression (2023) DOI
- Growth and dormancy control of myeloma cells by mesenchymal stem cells (2023) DOI
- Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers (2021) DOI
- PHF19 inhibition as a therapeutic target in multiple myeloma (2021) DOI
Grants & Funding
- Effect of TACI-lg and BAFFR-lg on primary myeloma growth in SCID-hu mice ZymoGenetics, Inc Principal Investigator
- Effect of VELCADE on Myeloma Bone Disease and Tumor Progression in a SCID-rab model for Primary Lymphoma Millennium Pharmaceuticals, Inc. Principal Investigator
- Inhibition of primary myeloma by Thrombospondin-1 Peptide Mimetic in vivo Abbott, Inc. Principal Investigator
- DEAP Awards - S Yaccoby - UAMS VCRI - FY26 UAMS Division of Research and Innovation Principal Investigator
- Anti-myeloma efficacy of PDACs/HPP Celgene Principal Investigator
- Effect of BI-505 ICAM-1 antibody on growth of myeloma cells in vitro and in vivo BioInvent Principal Investigator
- Inhibition of primary myeloma by Thrombospondin-1 Peptide Mimetic in vivo Abbott, Inc. Principal Investigator
- Role of SPRPs in the anti-myeloma response of osteoblasts Multiple Myeloma Research Foundation Principal Investigator
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics